S&P 500 slips, but losses kept in check as Nvidia climbs ahead of results
Khan Ruhi Ahmad, the Chief Business Officer of Caribou Biosciences , Inc. (NASDAQ:CRBU), recently reported a sale of company stock. According to a Form 4 filing with the Securities and Exchange Commission, Ahmad sold 3,564 shares of Caribou Biosciences common stock on February 21, 2025. The shares were sold at a weighted average price of $1.35, amounting to a total transaction value of approximately $4,811. This transaction comes as the stock trades near its 52-week low of $1.22, having declined nearly 80% over the past year. InvestingPro analysis suggests the stock may be undervalued at current levels.
The sale was conducted as part of a "sell to cover" transaction to fulfill tax withholding obligations related to the vesting of restricted stock units (RSUs) previously granted to Ahmad. This transaction was carried out under a Rule 10b5-1 trading plan, which was established before the 2023 amendments to the rule. The trading plan ensures the automatic sale of shares necessary to cover the tax obligations arising from the RSU vesting. Despite recent stock performance, InvestingPro data shows the company maintains strong liquidity with a current ratio of 7.38 and holds more cash than debt on its balance sheet.
In addition to the sale, Ahmad acquired 37,500 shares of common stock and 170,000 options to purchase common stock, both transactions occurring on February 20, 2025. These acquisitions were part of a compensation package, with the RSUs set to vest in four equal annual installments beginning February 20, 2026, and the options vesting over a period starting one year from the grant date. With a current market capitalization of $118 million, Caribou Biosciences represents a small-cap biotechnology investment opportunity. For deeper insights into CRBU’s valuation and financial health, access the comprehensive Pro Research Report available on InvestingPro.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.